Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Pharvaris N.V.NASDAQ: PHVS
Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q3 FY2026 weighted avg shares of 70.33M shares rose 13.0% year over year, behind the +16.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.0% toward the trailing-twelve-month pace of +16.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 59.16M EUR
- Year-over-year change
- +9.5%
- 4-year CAGR
- +18.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.16M | +9.5% |
| FY2024 | 2024-12-31 | 54.02M | +40.7% |
| FY2023 | 2023-12-31 | 38.39M | +14.3% |
| FY2022 | 2022-12-31 | 33.59M | +10.4% |
| FY2021 | 2021-12-31 | 30.41M | — |
Weighted Avg Shares vs competitors
How PHVS compares with its peers on the latest reported figures
- PHVS's LTM Sep 2026 weighted avg shares of 65.72M shares is the 6th highest of the 7 companies compared; the peer median is 80.21M shares.
- Its year-over-year change of +16.6% is the highest of 7, against a peer median of +3.3%.
- Over three fiscal years its annual growth of +20.8% compares with a peer median of +8.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 229.47M | +10.2% | +4.1% | |
| LTM Sep 2026 | 192.71M | +0.7% | +1.2% | |
| LTM Sep 2026 | 92.57M | +5.9% | +11.8% | |
| LTM Jun 2026 | 67.85M | +14.4% | +34.2% | |
| LTM Mar 2026 | 67.56M | -5.0% | -4.8% | |
| LTM Sep 2026 | 65.72M | +16.6% | +20.8% | |
| LTM Mar 2026 | 5.55M | -0.3% | +12.3% | |
| Peer median (excluding PHVS) | 80.21M | +3.3% | +8.0% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Selling, General & Admin | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Operating Expenses | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| EBITDA | (42.31M) | (86.56M) | (99.57M) | (145.42M) | (173.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (54.14M) | (86.71M) | (96.91M) | (145.69M) | (169.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 268 | 16 | 0 | 5.47M | 0 |
| Interest Expense | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income / Expenses | 11.48M | 11.06M | (2.91M) | 13.29M | (3.89M) |
| Income Before Tax | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | (42.73M) | (76.33M) | (100.88M) | (134.22M) | (175.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| EPS (Diluted) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| Weighted Avg Shares | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
| Weighted Avg Shares (Diluted) | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.